NEW YORK and XIANYANG, China, June 15 /PRNewswire-Asia-FirstCall/ -- Biostar Pharmaceuticals, Inc. (OTC Bulletin Board: BSPM) ("Biostar" or "the Company"), a leading manufacturer and supplier of pharmaceutical and medical nutrients addressing a variety of diseases and conditions through its wholly owned subsidiary, based in Xianyang, China, today announced it has retained HC International to lead a strategic communications program ("the IR program"). HC International will initiate a proactive and targeted investor relations campaign during the coming year. Matthew Hayden, president of HC International, and his team, will be advising the Company in all facets of public financial and corporate communications.
The Company's flagship product is the Xin Ao Xing Oleanolic Acid Capsule, the only SFDA approved OTC drug from the local level to the state level which treats chronic hepatitis B, a condition which affects 10% of the Chinese population. In addition, the company produces and sells two broad-based OTC drugs, two prescription drugs and ten nutrients. For 2008, revenues increased 113.5% to $33.9 million while net income increased 68.8% to $6.7 million.
HC International is a premier information resource for small-cap investors and investment professionals. HC International will help articulate Biostar Pharmaceuticals' strong product portfolio, its existing development pipeline and future growth opportunities to a much larger audience of investors, including institutional investors, hedge funds, independent portfolio managers, buy-side and sell-side analysts, small to large retail brokerage firms and accredited individual investors. Additionally, the firm will extend BSPM's investor awareness and shareholder communications program.
"The team at HC International is well-respected and has a proven track
record of representing successful China-based, U.S.-listed companies," said Mr.
|SOURCE Biostar Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved